Two-part Educational Webinar on Cell Therapy
Cell therapies have come of age, with nearly a dozen or more products commercialised globally and approximately one-thousand clinical trials underway. With an evolving regulatory environment and due to their unique and complex nature, cell therapy candidates present significant development challenges beginning in the preclinical phases of development.
In this two-part webinar, Evotec's expert Nicoletta Garbati and Rigenerand's Scientific Founder Prof Massimo Dominici* will provide an overview of cell therapy in preclinical development and oncology cell therapy with case study examples.
* As of 30th May 2022 Rigenerand Srl, a leading cell technology company, is part of Evotec. Read press release.
Key discussion points:
Part 1 - Cell Therapy and Preclinical Development
Presented by Nicoletta Garbati
- Review the ATMPs classification
- Review the GLP assessment pathway to a CT IND/IMPD submission vs. Standard Toxicology study
- Describe the Cell Therapy study design
- Outline tools to assess the distribution, persistence and shedding of cell therapy products in target and non-target tissues
Part 2 - Cell and Gene Therapies for Cancer: From Concept to Clinic
Presented by Prof. Massimo Dominici
- Somatic Cells-based Therapies
- Gene Modified Somatic Cell Based-Therapies
- Gene Modified Immune Cell Based-Therapies
- From Research to Clinic: The Rigenerand Cell Factory
- The Attrition Rate in Developing Cell and Gene Based-Therapies
About the Speakers
Part 1
If the video has not loaded above, please click here.
Part 2
If the video has not loaded above, please click here.